Bailey, S, Gerada, C, Lester, H, Shiers, D.
The cardiovascular health of young people with severe mental illness: addressing an epidemic within an epidemic. Psychiatrist
2012; 36: 375–8.
Nielsen, J, Skadhede, S, Correll, CU. Antipsychotics associated with the development of type 2 diabetes in antipsychotic-naive schizophrenia patients. Neuropsychopharm
2010; 35: 1997–2004.
Lahti, M, Tiihonen, J, Wildgust, H, Beary, M, Hodgson, R, Kajantie, E, et al.
Cardiovascular morbidity, mortality and pharmacotherapy in patients with schizophrenia. Psychol Med
2012; 42: 2275–85.
Kilbourne, AM, Morden, NE, Austin, K, Ilgen, M, McCarthy, JF, Dalack, G, et al.
Excess heart-disease-related mortality in a national study of patients with mental disorders: identifying modifiable risk factors. Gen Hosp Psychiatry
2009; 31: 555–63.
Beary, M, Hodgson, R, Wildgust, HJ. A critical review of major mortality risk factors for all-cause mortality in first-episode schizophrenia: clinical and research implications. J Psychopharmacol
2012; suppl. 26: S52–61.